New asthma drug formulation put to the test in healthy adults
NCT ID NCT07231861
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two oral formulations of pranlukast, a drug used for asthma and allergic rhinitis, to see if they are equivalent. Sixty healthy adults will receive a single dose of each version in random order under fasting conditions. The main goal is to measure drug levels in the blood, not to treat any condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pranlukast hydrate
What this could lead to
If successful, this study could confirm that the new formulation of pranlukast works the same as the existing one, potentially offering a generic alternative for asthma and allergy treatment.
What could go wrong
This is an early Phase 1 trial in healthy volunteers, not patients. It only checks drug levels in the blood, not whether the drug actually helps symptoms. The results may not predict real-world effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERENNIAL ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
H Plus Yangji Hospital
Seoul, 08779, South Korea